MX2010009401A - Forma cristalina de derivado de fenilamino pirimidina. - Google Patents

Forma cristalina de derivado de fenilamino pirimidina.

Info

Publication number
MX2010009401A
MX2010009401A MX2010009401A MX2010009401A MX2010009401A MX 2010009401 A MX2010009401 A MX 2010009401A MX 2010009401 A MX2010009401 A MX 2010009401A MX 2010009401 A MX2010009401 A MX 2010009401A MX 2010009401 A MX2010009401 A MX 2010009401A
Authority
MX
Mexico
Prior art keywords
crystal form
pyrimidine derivative
formula
phenylamino pyrimidine
phenylamino
Prior art date
Application number
MX2010009401A
Other languages
English (en)
Inventor
Amala Kishan Kompella
Sreenivas Rachakonda
Nannapaneni Venkaiah Chowdary
Bhujanga Rao Adibhatla Kalisatya
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/042,247 external-priority patent/US8067422B2/en
Priority claimed from US12/042,235 external-priority patent/US8183253B2/en
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MX2010009401A publication Critical patent/MX2010009401A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una forma particular de la (3,5-bis-trifluorometil)-N-[4-metil-3-(4-piridin-3-il-pirimidin-2 -ilamino)-fenili-benzamida (fórmula I), a procesos para su preparación, a las composiciones farmacéuticas que contienen esta forma cristalina, y a su uso como un agente anti-tumoral en los seres humanos. El compuesto de la fórmula I, también conocido como AN-019, es la fórmula (I).
MX2010009401A 2008-03-04 2009-03-02 Forma cristalina de derivado de fenilamino pirimidina. MX2010009401A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/042,247 US8067422B2 (en) 2008-03-04 2008-03-04 Crystal form of phenylamino pyrimidine derivatives
US12/042,235 US8183253B2 (en) 2004-09-09 2008-03-04 Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
PCT/IB2009/005421 WO2009109867A2 (en) 2008-03-04 2009-03-02 Crystal form of phenylamino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2010009401A true MX2010009401A (es) 2010-09-24

Family

ID=40802116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009401A MX2010009401A (es) 2008-03-04 2009-03-02 Forma cristalina de derivado de fenilamino pirimidina.

Country Status (18)

Country Link
EP (1) EP2265599B1 (es)
JP (1) JP2011513380A (es)
KR (1) KR20100126464A (es)
CN (1) CN102015681B (es)
AP (1) AP2651A (es)
AR (1) AR070783A1 (es)
AU (1) AU2009220856B2 (es)
CA (1) CA2716413A1 (es)
CO (1) CO6300946A2 (es)
EA (1) EA019223B1 (es)
GE (1) GEP20135882B (es)
IL (1) IL207750A0 (es)
MA (1) MA32142B1 (es)
MX (1) MX2010009401A (es)
MY (2) MY183331A (es)
NZ (1) NZ587518A (es)
WO (1) WO2009109867A2 (es)
ZA (1) ZA201005957B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
KR102012398B1 (ko) 2009-11-05 2019-08-20 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9110310B2 (en) 2011-03-18 2015-08-18 Johnson & Johnson Vision Care, Inc. Multiple energization elements in stacked integrated component devices
CN107337659A (zh) 2011-05-04 2017-11-10 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
SI2870157T1 (en) 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S.A. SELECTIVE PI3K-DELTA INHIBITORS
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1786799T1 (sl) * 2004-09-09 2012-12-31 Natco Pharma Limited Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze

Also Published As

Publication number Publication date
AP2651A (en) 2013-04-25
ZA201005957B (en) 2011-10-26
CN102015681B (zh) 2013-08-28
EP2265599A2 (en) 2010-12-29
MY183331A (en) 2021-02-18
IL207750A0 (en) 2010-12-30
AP2010005390A0 (en) 2010-10-31
NZ587518A (en) 2012-09-28
EA201071019A1 (ru) 2011-08-30
CA2716413A1 (en) 2009-09-11
AU2009220856A2 (en) 2010-09-16
CO6300946A2 (es) 2011-07-21
WO2009109867A2 (en) 2009-09-11
EP2265599B1 (en) 2013-11-20
MA32142B1 (fr) 2011-03-01
AU2009220856B2 (en) 2012-07-26
MY175373A (en) 2020-06-23
AR070783A1 (es) 2010-05-05
KR20100126464A (ko) 2010-12-01
AU2009220856A1 (en) 2009-09-11
EA019223B1 (ru) 2014-02-28
CN102015681A (zh) 2011-04-13
WO2009109867A3 (en) 2009-12-17
GEP20135882B (en) 2013-07-25
JP2011513380A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
MX2010009401A (es) Forma cristalina de derivado de fenilamino pirimidina.
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
JO3121B1 (ar) مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
NZ604035A (en) Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
TW200732323A (en) Organic compounds
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
GEP20146125B (en) Aminopyrimidines as syk inhibitors
ECSP055601A (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
GEP20135983B (en) 1-benzyl-3-hydroxymethylindazole derivatives and usage therein treatment of diseases based on mcp-1, cx3cr1 and p40 expression
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY151295A (en) Pyrimidyl indoline compound
TW200745122A (en) New compounds I
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
EA200702375A1 (ru) Производные мочевины, способы их получения и применения

Legal Events

Date Code Title Description
FG Grant or registration